Article

Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: A population-based study

University of Milan, Milano, Lombardy, Italy
Journal of the Neurological Sciences (Impact Factor: 2.26). 01/2007; 250(1-2):45-9. DOI: 10.1016/j.jns.2006.06.027
Source: PubMed

ABSTRACT The El Escorial and the revised Airlie House diagnostic criteria for amyotrophic lateral sclerosis (ALS) were introduced to select patients for clinical trials. Heterogeneity of clinical presentation at onset and delay in diagnosis may decrease the likelihood for trial entry.
Identify risk factors for delay in the diagnosis and trial exclusion.
ALS incident cases were identified with El Escorial (EEC) and Airlie House criteria (AHC) through a population-based registry established in Puglia, Southern Italy, in the years 1998-99.
130 ALS incident cases were diagnosed with a median interval between onset of symptoms and diagnosis of 9.3 months and not different across both EEC and AHC categories. Twenty percent of cases were not eligible for clinical trials according to the AHC. About 5% of subjects in this series died with only lower motor neuron signs. Predictors for delay in the diagnosis were age between 65 and 75 years and spinal onset while fasciculations and cramps as first symptoms were predictors of exclusion from trials.
In this population-based series, diagnostic delay was longer in subjects with spinal onset and age between 65 and 75 and fasciculation as first symptoms. About 80% of incident cases were trial eligible with AHC criteria. However, a significant number of subjects with ALS, characterized by a limited spread of signs, were not trial eligible while alive.

Download full-text

Full-text

Available from: Giancarlo Logroscino, Nov 26, 2014
1 Follower
 · 
116 Views
  • Source
    • "Bulbar presentation was associated with a shorter time to diagnosis [4] [8] [9]. We suggest that this implies recognition that bulbar symptoms are not derived from spinal cord or root lesions; indeed, neurologists associate progressive bulbar weakness as typically suggestive of ALS. "
    [Show abstract] [Hide abstract]
    ABSTRACT: We studied the limitations to early diagnosis in amyotrophic lateral sclerosis (ALS). The diagnostic process was assessed in 120 consecutive patients, including onset, interval to diagnosis, investigations, specialist assessment and pre-diagnostic management. Times from onset to first consultation (T1), second consultation (T2) and diagnosis (TD) were considered. Predictors of diagnostic delay were determined by multivariate logistic regression, adjusted for gender, age, clinical manifestations, and specialism of the first and second consultants. There were 101 consecutive ALS patients with complete datasets (69% men; median age at diagnosis 61.5 years). The mean TD and median TD were respectively 10.1 and 9.5 months. In 55%, the first consultant was a general practitioner (GP), in 16% a neurologist and in 14% an orthopedist. The diagnosis of ALS was made by non-neurologists in 9 patients. The odds of delayed diagnosis (≥ 12 months) were higher (1.56; 0.19–12.56) in younger patients (≤ 45 years) (p < 0.05). Female gender (0.56; 0.29–1.70) and bulbar-onset (0.56; 0.29–1.70) were independently associated with earlier diagnosis (p < 0.05). Assessment by a neurologist at the first (0.32; 0.19–2.46) or second consultation (0.87; 0.21–1.21) was associated with a shorter diagnosis time (< 12 months) (p < 0.05). We conclude that diagnostic delay mainly resulted from delayed referral from non-neurologist physicians to a neurologist. Moreover, incomplete neurophysiological investigation had a relevant impact.
    Journal of the Neurological Sciences 08/2014; DOI:10.1016/j.jns.2014.06.003 · 2.26 Impact Factor
  • Source
    • "These mechanisms are not exclusive of the mutant SOD1G93A mice. In fact some of them can be extrapolated from studies using different animal models or examining patients with both familial and sporadic ALS [1] [3] [25]. Therefore, the SOD1G93A mouse model is regarded as a valuable paradigm to gain insights into the pathobiology of sporadic ALS. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Amyotrophic Lateral Sclerosis (ALS), which accounts for the majority of motor neuron disorders, is a progressive and fatal neurodegenerative disease leading to complete paralysis of skeletal muscles and premature death usually from respiratory failure. About 10% of all ALS cases are inherited, with the responsible gene having been identified in approximately 25% of these individuals. Mutations in the copper-zinc superoxide dismutase (SOD1) gene were the first to be recognized nearly twenty years ago, and since then different animal models, in particular transgenic rodents, have been developed. They replicate many of the clinical, neuropathological and molecular features of ALS patients and have contributed significantly to our understanding of the pathogenic mechanisms of this disease. Although results obtained so far with mutant SOD1 mice have not translated into effective therapies in ALS patients, these models still represent the only experimentally accessible system to study multiple aspects of disease pathogenesis and to provide proof-of-principle for the development of new therapeutic strategies. This review will examine the most recent discoveries obtained from these animal models in an attempt to elucidate the complex mechanisms of the disease. In particular it will focus on the contribution of multiple cell types in governing the disease development and progression.
    CNS & neurological disorders drug targets 08/2010; 9(4):491-503. DOI:10.2174/187152710791556096 · 2.70 Impact Factor
  • Source
    • "The clinical diagnosis of ALS is often not confirmed until nearly a year after symptoms are detected ( Brooks , 2000 ; Zoccolella et al . , 2006 ) . Generally , ALS presents itself with both upper and lower motoneuron symptoms and is generally classified as arm , leg , or bulbar onset . Upper motoneuron signs include hyper - reflexia , increased tone , and clonus while lower motoneuron signs include weakness , fatigue , muscle atrophy , non - specific muscle cramping , and fasci"
    [Show abstract] [Hide abstract]
    ABSTRACT: Meaningful body movements depend on the interplay between synaptic inputs to motoneurons and their intrinsic properties. Injury and disease often alter either or both of these factors and cause motoneuron and movement dysfunction. The ability of the motoneuronal membrane to generate persistent inward currents (PICs) is especially potent in setting the intrinsic excitability of motoneurons and can drastically change the motoneuron output to a given input. In this article, we review the role of PICs in modulating the excitability of spinal motoneurons during health, and their contribution to motoneuron excitability after spinal cord injury (SCI) and in amyotrophic lateral sclerosis (ALS) leading to exaggerated long-lasting reflexes and muscle spasms, and contributing to neuronal degeneration, respectively.
    Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology 05/2010; 121(10):1669-79. DOI:10.1016/j.clinph.2009.12.041 · 2.98 Impact Factor
Show more